Top Markets
Coin of the day
Albireo Pharma, Inc. Albireo Pharma, Inc.

Albireo Pharma, Inc.

ALBO
株式のランク #12828
Albireo Pharma, Inc. is a biopharmaceutical company with marketed products,... Albireo Pharma, Inc. is a biopharmaceutical company with marketed products, dedicated to researching, developing, and commercializing new treatments that modify bile acids. The company primarily targets rare liver diseases in children, as well as various other conditions affecting the liver or digestive system. Its portfolio includes Bylvay, a treatment approved for progressive familial intrahepatic cholestasis. Bylvay is also in advanced (Phase III) clinical trials for further pediatric indications such as biliary atresia and Alagille syndrome, which are both uncommon and serious childhood disorders. Additionally, Albireo offers Elobixibat, prescribed for the management of persistent constipation and other functional gastrointestinal issues. Albireo is further advancing its pipeline with A3907, currently undergoing early-stage (Phase I) clinical investigation for adult liver diseases, and A2342, a preclinical candidate designed to address adult viral and liver conditions. The company holds a licensing agreement with EA Pharma Co., Ltd. concerning the development and market rollout of Elobixibat. Albireo Pharma, Inc.'s headquarters are located in Boston, Massachusetts.
株価
$44.15
最終同期: 2023-03-02
時価総額
$545.52M
変化(1日)
-0.23%
変化(1年)
0.00%
US
取引 Albireo Pharma, Inc. (ALBO)

カテゴリー

Albireo Pharma, Inc.(ALBO)のEPS
2026 時点のEPS TTM: 0
Albireo Pharma, Inc.の最新の財務報告と株価によると、同社の現在のEPS(TTM)は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
Albireo Pharma, Inc.のEPS履歴(2026から2026まで)
各年末時点のEPS
EPS 変化
提供された日付のデータは十分ではありません。
同様の企業または競合他社のEPS
企業 EPS EPSの差
$17.32 -
US
$27.74 -
NL
$-5.29 -
AU
$-7.98 -
US
- -
CH